Eli Lilly Chair & CEO Dave Ricks tells CNBC’s Angelica Peebles that with the approval of the company’s GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the globe. Ricks says that while 1 in 10 Americans are currently using a GLP-1, in China only 0.5% of the population has tried one, pointing to a large untapped market opportunity internationally. ...

Investment Rating - The report maintains a "BUY" rating for Pharmaron Beijing, indicating a potential return of over 15% over the next 12 months [18]. Core Insights - Pharmaron reported a revenue growth of 14.8% YoY to RMB 14.10 billion and a non-IFRS adjusted net profit increase of 13.0% YoY to RMB 1.82 billion for 2025, both exceeding estimates [1][2]. - The company expects revenue growth of 12-18% YoY in 2026, factoring in a negative impact of 3 percentage points from foreign exchange [1]. - A significant CDMO deal with Eli Lilly is expected to enhance future growth, with Eli Lilly investing US$200 million to support Pharmaron's technical capabilities [9]. Financial Performance - For FY25, revenue was RMB 14,095 million, with a YoY growth of 14.8% and adjusted net profit of RMB 1,816 million, reflecting a 13.0% YoY increase [2]. - Revenue projections for FY26, FY27, and FY28 are RMB 16,410 million, RMB 19,019 million, and RMB 21,855 million, respectively, with YoY growth rates of 16.4%, 15.9%, and 14.9% [2]. - Adjusted net profit is expected to reach RMB 2,156 million, RMB 2,537 million, and RMB 2,955 million for FY26, FY27, and FY28, with corresponding YoY growth rates of 18.7%, 17.7%, and 16.5% [2]. Valuation - The target price for Pharmaron has been raised from RMB 38.08 to RMB 39.00, reflecting a 39.4% upside from the current price of RMB 27.98 [3]. - The DCF-based valuation incorporates a WACC of 9.32% and a terminal growth rate of 2.0% [9][12]. Market Position - Revenue from global Top 20 pharma clients surged by 29.4% YoY, significantly outpacing the company's overall growth, while revenue from European clients grew by 27.4% YoY [9]. - Newly signed orders increased by over 14% YoY, continuing a robust growth trend following a greater than 20% YoY increase in 2024 [9].

Core Viewpoint - The recent collaboration between Insilico Medicine and Eli Lilly, involving a total deal value of $2.75 billion, highlights the growing significance of AI in drug development, particularly in the oral GLP-1 drug space, which is currently a key competitive point in the global pharmaceutical market [2][3][10]. Group 1: Transaction Details - Insilico Medicine announced a partnership with Eli Lilly, which includes an upfront payment of $115 million and a total deal value of $2.75 billion, along with potential sales royalties post-product launch [2][3]. - The deal's upfront payment is twice the company's projected total revenue for 2025, which is estimated at $56.2 million, and the total deal value exceeds the company's previous business development (BD) agreements combined, which amounted to $2.174 billion [2][3]. - Following the announcement, Insilico's stock price surged by 15% intraday, closing up 2%, and the deal triggered antitrust scrutiny in the U.S. due to its substantial cash component [2][3]. Group 2: Strategic Implications - Insilico's CEO emphasized the company's commitment to independent development, suggesting that if a single BD deal can achieve such a valuation, the acquisition valuation should be even higher [2][3]. - The collaboration is seen as a strong endorsement of Insilico's Pharma AI platform, which has already facilitated the development of over 20 clinical/IND-stage assets, generating $130 million in upfront cash flow [10][12]. - The partnership reflects a broader trend where multinational pharmaceutical companies are increasingly viewing Chinese biotech firms as valuable R&D partners, effectively outsourcing their development needs [16][18]. Group 3: Market Context - The oral GLP-1 drug market is currently dominated by products like Novo Nordisk's oral semaglutide, which has been approved in the U.S., and Eli Lilly's Orforglipron, which is under review, with peak sales expectations reaching $40 billion [8][10]. - Insilico's oral GLP-1 candidate is part of a cardiovascular and metabolic product portfolio developed using its Pharma AI platform, which aims to improve patient compliance by offering a weekly dosing regimen [10][12]. - The trend of "joint development" in BD agreements is becoming more common, allowing biotech firms to retain decision-making rights and substantial equity in product development, contrasting with traditional CXO models [16][18].

Core Viewpoint - The collaboration between Insilico Medicine and Eli Lilly represents a significant transaction in the AI pharmaceutical sector, valued at $2.75 billion, with an upfront payment of $115 million, highlighting the growing trend of AI-driven drug development partnerships in the industry [1][2]. Group 1: Transaction Details - Insilico Medicine announced a collaboration with Eli Lilly involving an upfront payment of $115 million and a total deal value of $2.75 billion, which includes potential sales revenue sharing post-product launch [1]. - The transaction is centered around a preclinical oral GLP-1 drug, with future research collaborations planned based on Insilico's Pharma AI technology platform [1][10]. - The total deal value exceeds the cumulative amount of all previous business development (BD) agreements, indicating a significant increase in the company's valuation and market interest [1][2]. Group 2: Market Impact and Reactions - Following the announcement, Insilico's stock experienced a surge, with an intraday increase of 15% and a closing rise of 2% [1]. - The deal has triggered antitrust scrutiny in the U.S. due to its substantial cash component, leading to speculation about a potential acquisition of Insilico by Eli Lilly [1]. - Insilico's CEO emphasized the company's commitment to independent development and the strong endorsement from Eli Lilly, which has attracted further inquiries from other major pharmaceutical companies [1][2]. Group 3: Industry Context - The collaboration reflects a broader trend in the biotech industry, where AI-native companies are becoming key players in the business development landscape, securing substantial upfront payments and total deal values [2][12]. - Insilico's partnership aligns with similar recent collaborations in the industry, such as those between Innovent Biologics and Eli Lilly, and Frontier Biotech and GSK, which also focus on early-stage product development [11]. - The deal structure allows Insilico to maintain decision-making authority in the development process, differentiating it from traditional contract research organizations (CROs) [11][12]. Group 4: Future Prospects - Insilico's leadership expressed confidence in achieving milestone revenues, estimating a 60-70% chance of success based on product quality and development timelines [9]. - The collaboration is expected to enhance Insilico's capabilities in building a global clinical and commercialization team, leveraging the cash flow from BD agreements to support larger-scale clinical trials in the future [2][12]. - The partnership with Eli Lilly is seen as a validation of Insilico's AI-driven drug development approach, potentially leading to more collaborations and increased market presence [5][12].

Group 1 - The AACR conference is expected to catalyze data for innovative drugs, with over 100 Chinese pharmaceutical companies presenting nearly 400 research results, enhancing the visibility of companies like HengRui, BeiGene, and others in key therapeutic areas [4][7] - The conference is likely to boost sentiment in the innovative drug sector, as China has shown stable output in multiple mainstream tracks, including ADCs and dual antibodies, indicating a significant presence and engagement in academic discussions [7] - The oral GLP-1 receptor agonist Orforglipron is anticipated to be approved in Q2 2026, marking a shift to oral weight-loss medications, which could significantly expand the patient population and create substantial investment opportunities in the supply chain [8] Group 2 - The pharmaceutical and biotechnology sector's TTM-PE is at 44.16 times, representing a 217% premium over the CSI 300, indicating a reasonable valuation compared to historical lows [9] - The healthcare sector has shown a mixed performance, with the pharmaceutical sector rising by 1.56%, ranking fourth among 27 sub-industries, while chemical raw materials and medical services saw significant gains [13][16] - Individual stock performance highlights include notable gains for Meinuohua (40.73%) and Fuxiang Pharmaceutical (27.61%), while Jichuan Pharmaceutical and Baiyunshan experienced declines [19][22] Group 3 - Recent industry dynamics include Novo Nordisk's approval of a weekly long-acting insulin in the U.S., and Haihe Pharmaceutical's selective PI3Kα inhibitor receiving approval in Japan, showcasing ongoing innovation in diabetes and cancer treatments [20][21] - Corcept Therapeutics' approval of a new ovarian cancer drug in the U.S. and Ionis' submission for a rare disease treatment reflect the active pipeline in oncology and rare diseases [24][25] - GSK's long-acting monoclonal antibody for asthma and the approval of a new eye treatment by Yuanda Pharmaceutical demonstrate the expanding therapeutic options in respiratory and ophthalmic care [32][33]

Group 1 - The core viewpoint is that the expectation of peace talks is unlikely to materialize in the short term, primarily due to the unresolved issues surrounding Iran's nuclear development, which may lead to higher costs for negotiations and increased oil price volatility [1] - The energy and chemical sectors, which initially benefited from the war, have seen a decline in trading volume and may experience a second wave of market activity as the first round of trading concludes [1] - There is a focus on mid-term investment opportunities in high-weight value sectors such as energy, public utilities, insurance, and banking, which are expected to be favorable for low-cost entry [2] Group 2 - The innovative drug sector is experiencing a significant resurgence, driven by positive market sentiment and upcoming catalysts from conferences like AACR and ASCO, indicating a potential for fundamental and emotional resonance in the sector [3] - Eli Lilly's oral GLP-1 receptor agonist, Orforglipron, has shown superior results in clinical trials compared to existing treatments, with an expected market approval in April 2026, marking a critical phase for the global oral weight-loss drug industry [3][4] - The competitive landscape for oral GLP-1 small molecules is intensifying, with several domestic companies also advancing in clinical trials, presenting substantial market opportunities for local production chains [4]

Core Viewpoint - Eli Lilly and Insilico Medicine have deepened their collaboration with a drug development partnership worth up to $2.75 billion, including an upfront payment of $115 million, which has triggered antitrust scrutiny from the FTC and rumors of a potential acquisition of Insilico by Eli Lilly [2]. Group 1: Collaboration Details - The partnership aims to expand Eli Lilly's use of Insilico's AI drug development engine, Pharma.AI, to develop new therapies [2]. - Eli Lilly has obtained global exclusive licensing rights for a preclinical oral GLP-1 weekly formulation developed by Insilico [2]. Group 2: Market Context - In the GLP-1 sector, Eli Lilly has surpassed Novo Nordisk with its dual receptor agonist Tirzepatide compared to Semaglutide [3]. - Oral formulations are considered to have higher compliance rates, with Eli Lilly's small molecule GLP-1 receptor agonist Orforglipron having submitted applications for obesity and type 2 diabetes treatment in the US and China [3]. - The candidate drug from Insilico aims to improve dosing frequency to once a week, compared to daily dosing for existing oral GLP-1 medications [3].

Core Viewpoint - Eli Lilly and Company (NYSE: LLY) is identified as a strong investment opportunity, particularly due to its promising prescription data for GLP-1 medications, with a Buy rating reiterated by Jefferies and a price target of $1,300 [1]. Group 1: Prescription Data - Oral Wegovy achieved approximately 89,300 IMS prescriptions and 76,800 Symphony prescriptions in its 10th week post-launch, surpassing the initial launches of injectable Wegovy and Zepbound [1]. - Other GLP-1 drugs experienced declines, with Zepbound prescriptions falling 3% to 17,100, Mounjaro decreasing to 13,100 after a 2% drop, and injectable Wegovy declining 3% to 9,710 [3]. Group 2: Future Projections - The data for oral Wegovy is seen as positive for Eli Lilly's Orforglipron, which has a PDUFA date set for April 10, 2026. Projections estimate Orforglipron revenue to reach $2 billion in 2026, exceeding the consensus of $1.55 billion, while Lilly's total revenue guidance is between $80 billion to $83 billion [4]. Group 3: Company Overview - Eli Lilly and Company is involved in the development, manufacturing, discovery, and sale of pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [4].

Investment Rating - The industry rating is "Outperform the Market" [7][70] Core Insights - The enthusiasm for innovative drugs is returning, with a focus on investment opportunities in the Eli Lilly oral weight loss drug supply chain [3][5] - Eli Lilly's oral weight loss drug Orforglipron is expected to receive FDA approval in April 2026, which is a key catalyst for the industry [5][19] - The report emphasizes the importance of innovative drugs and medical devices as the main themes for the pharmaceutical industry in 2026, with a focus on revenue realization and high-growth performance [6][30] Summary by Sections 1. Weekly Performance of Recommended Pharmaceutical Portfolio - The recommended portfolio outperformed the pharmaceutical index by 4.9 percentage points and the overall market by 7.8 percentage points [14][15] 2. Eli Lilly's Oral Weight Loss Drug Orforglipron Approval - Orforglipron has shown superior results in the ACHIEVE-3 study compared to oral semaglutide, with significant improvements in A1C reduction and weight loss [20][21] - The drug is expected to be launched in 2026, with a focus on investment opportunities in the supply chain, including companies like WuXi AppTec and Kelun Pharmaceutical [5][25] 3. Weekly Market Review and Hotspot Tracking (March 23-27, 2026) - The CITIC Pharmaceutical Index fell by 1.4% but outperformed the CSI 300 Index by 2.9 percentage points [4][30] - The top-performing stocks included Meinuohua (+40.7%), Wanbangde (+38.8%), and Fuxiang Pharmaceutical (+27.6%) [43][49] - The report highlights the recovery of innovative drug sentiment and the expected significant returns in the upcoming months due to upcoming conferences and strong revenue growth [6][30]

Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, emphasizing the importance of supply chain (CXO and upstream sectors) for 2026 [4]. Core Insights - The pharmaceutical industry is expected to enter a prosperous performance phase in 2026, driven by a combination of domestic and international demand recovery and innovation iterations [2]. - The report highlights the strong performance of leading companies in the CXO sector, which are expected to benefit from the recovery of both domestic and international markets [3]. - The report identifies specific investment opportunities in the supply chain, particularly in the CDMO sector, as well as in clinical CRO and safety evaluation sectors, which are anticipated to benefit from the domestic innovation wave [3]. Summary by Sections 1. Supply Chain Focus for 2026 - The CXO industry is in an upward trend, with leading companies demonstrating strong performance and the ability to secure large orders due to their integrated platforms and global presence [13]. - The report notes that the performance of clinical CRO and safety evaluation sectors has shown marginal improvement, with expectations for further performance validation in 2026 [14]. - The report emphasizes the potential for significant growth in the peptide therapy market, predicting a market size of approximately $79.6 billion by 2025, with a compound annual growth rate (CAGR) of nearly 15.8% from 2024 to 2030 [26][29]. 2. Market Review and Hotspot Tracking - The pharmaceutical index experienced a decline of 2.77% from March 16 to March 20, 2026, underperforming compared to the broader market indices [45]. - The report indicates that the pharmaceutical sector's transaction volume was approximately 409.68 billion yuan, accounting for 3.30% of the total market transaction volume [67]. - The report highlights the performance of specific stocks, with notable gains from companies like *ST Jingfeng and Sanofi, while others like Changyao and Xiangyu Medical faced significant declines [71]. 3. Investment Recommendations - The report suggests focusing on three lines in the upstream biotechnology sector: 1) companies benefiting from early-stage innovation trends, 2) companies experiencing recovery in new orders, and 3) leading clinical CRO companies that are expected to gain from the innovation wave [43]. - In the CDMO sector, the report recommends companies with a strong foothold in the peptide supply chain, as well as those positioned to benefit from ADC trends and small nucleic acid developments [43].